Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Other Operating Expenses: 2019-2021

Historic Other Operating Expenses for Beam Therapeutics (BEAM) over the last 2 years, with Mar 2021 value amounting to -$1.2 million.

  • Beam Therapeutics' Other Operating Expenses rose 43.56% to -$1.2 million in Q1 2021 from the same period last year, while for Mar 2021 it was -$60.9 million, marking a year-over-year decrease of 1102.69%. This contributed to the annual value of -$61.8 million for FY2020, which is 1849.31% down from last year.
  • Per Beam Therapeutics' latest filing, its Other Operating Expenses stood at -$1.2 million for Q1 2021, which was up 97.83% from -$54.7 million recorded in Q4 2020.
  • In the past 5 years, Beam Therapeutics' Other Operating Expenses registered a high of $2.9 million during Q3 2020, and its lowest value of -$54.7 million during Q4 2020.
  • Over the past 3 years, Beam Therapeutics' median Other Operating Expenses value was -$1.3 million (recorded in 2019), while the average stood at -$8.2 million.
  • Within the past 5 years, the most significant YoY rise in Beam Therapeutics' Other Operating Expenses was 392.46% (2020), while the steepest drop was 3,596.08% (2020).
  • Quarterly analysis of 3 years shows Beam Therapeutics' Other Operating Expenses stood at -$1.5 million in 2019, then slumped by 3,596.08% to -$54.7 million in 2020, then soared by 43.56% to -$1.2 million in 2021.
  • Its Other Operating Expenses stands at -$1.2 million for Q1 2021, versus -$54.7 million for Q4 2020 and $2.9 million for Q3 2020.